The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis
Abstract
BACKGROUND: Transthyretin (TTR) amyloidosis is a rare, life-threatening, systemic, autosomal dominant condition occurring in adults, with two main forms: hereditary (associated with TTR gene mutations) and wild-type. Studies indicate considerable heterogeneity in disease presentation, with predominantly polyneuropathic, predominantly cardiac, or mixed phenotypes. METHODS: THAOS - the Transthyretin Amyloidosis Outcomes Survey - is the first global, multicenter, longitudinal, observational survey that collects data on the natural history of TTR amyloidosis (ClinicalTrials.gov: NCT00628745). This paper presents data on signs and symptoms, neurological and cardiac assessments, biomarkers and quality of life in the patients enrolled in THAOS from its inception in December 2007 to September 2011. RESULTS: At the time of this analysis, data were available from 611 symptomatic patients with hereditary TTR amyloidosis, 67 symptomatic patients with wild-type TTR amyloidosis, and 274 currently asymptomatic individuals with a TTR mutation. Nineteen countries were participating in the registry. The largest patient groups came from Portugal (n = 453), the USA (n = 129), Italy (n = 70), and Japan (n = 68). Predominant symptom presentation in patients with hereditary TTR amyloidosis differed according to the underlying disease-causing mutation (polyneuropathy for Val30Met, cardiomyopathy for Val122Ile and Leu111Met, and mixed for Glu89Gln). However, each mutation was associated with clear multisystem involvement. Similarly, although cardiomyopathy was predominant in patients with wild-type TTR amyloidosis, many also showed symptoms consistent with neuropathy. Quality of life in patients with hereditary TTR amyloidosis, but not asymptomatic carriers of disease-causing mutations, was severely impaired relative to that of the age-matched general US population. CONCLUSIONS: This preliminary analysis highlights the considerable phenotypic heterogeneity for neurological and cardiac manifestations in patients with hereditary and wild-type TTR amyloidosis and the necessity of providing multidisciplinary care. THAOS registry data will help better characterize the diverse presentation and course of TTR amyloidosis worldwide and aid in improving and standardizing diagnosis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Falk, R. H., Comenzo, R. L., & Skinner, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371306 · Cited by 1,180
Breathnach, S. M. (1988) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(88)70001-8 · Cited by 615
Variant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black Americans
Jacobson, D. R., Pastore, R. D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F. S., & Buxbaum, J. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702133360703 · Cited by 554
Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics
Hammarström, P., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2003) · Science · doi:10.1126/science.1079589 · Cited by 525
Tabulation of human transthyretin (TTR) variants, 2003
Connors, L. H., Lim, A., Prokaeva, T., Roskens, V. A., & Costello, C. E. (2003) · Amyloid · doi:10.3109/13506120308998998 · Cited by 505
The molecular biology and clinical features of amyloid neuropathy
Benson, M. D., & Kincaid, J. C. (2007) · Muscle & Nerve · doi:10.1002/mus.20821 · Cited by 447
Transthyretin-Related Familial Amyloidotic Polyneuropathy
Ando, Y., Nakamura, M., & Araki, S. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1057 · Cited by 416
Glynn, L. E. (1981) · PubMed Central · Cited by 412
A National Catalog of Preference-Based Scores for Chronic Conditions in the United States
Sullivan, P. W., Lawrence, W. F., & Ghushchyan, V. (2005) · Medical Care · doi:10.1097/01.mlr.0000172050.67085.4f · Cited by 388
Type I (Transthyretin Met30) Familial Amyloid Polyneuropathy in Japan: Early- vs Late-Onset Form
Koike, H. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1771 · Cited by 266
Sousa, A., Coelho, T., Barros, J., & Sequeiros, J. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320600606 · Cited by 238
Self-citationVinik, E. J., Hayes, R. P., Oglesby, A., Bastyr, E., Barlow, P., Ford-Molvik, S. L., & Vinik, A. I. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.497 · Cited by 235
SUHR, O., DANIELSSON, Å., HOLMGREN, G., & STEEN, L. (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb01106.x · Cited by 209
Self-citationThe Genetics of the Amyloidoses
Buxbaum, J. N., & Tagoe, C. E. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.543 · Cited by 154
Forty years of experience with type I amyloid neuropathy. Review of 483 cases
Coutinho, P., da Silva, A. L., Lopes, J. M., Resende, P.-E. A., Silva, A. M. D., Resende, L. A. L., Silva, A. M.-D., Filho, J. D. L., & Barbosa, A. (1980) · Cited by 149
Pathogenesis of and Therapeutic Strategies to Ameliorate the Transthyretin Amyloidoses
Sekijima, Y., Kelly, J. W., & Ikeda, S. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786404155 · Cited by 139
Buxbaum, J. N., Alexander, A. A., Koziol, J. A., Tagoe, C. E., Fox, E. R., & Kitzman, D. W. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.02.006 · Cited by 107
Steen, L., & Ek, B. (1983) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1983.tb08613.x · Cited by 101
Heart complications in familial transthyretin amyloidosis: impact of age and gender
Hörnsten, R., Pennlert, J., Wiklund, U., Lindqvist, P., Jensen, S. M., & Suhr, O. B. (2010) · Amyloid · doi:10.3109/13506129.2010.483114 · Cited by 92
Self-citationFamilial amyloidotic polyneuropathy in Sweden: a pedigree analysis.
Drugge, U., Andersson, R., Chizari, F., Danielsson, M., Holmgren, G., Sandgren, O., & Sousa, A. (1993) · Journal of Medical Genetics · doi:10.1136/jmg.30.5.388 · Cited by 90
Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His
Blevins, G., Macaulay, R. J. B., Harder, S. L., Fladeland, D. A., Yamashita, T., Yazaki, M., Asl, K. H., Benson, M. D., & Donat, J. R. (2003) · Neurology · doi:10.1212/01.wnl.0000065901.18353.ab · Cited by 79
Amyloidosis: Diagnosis and Treatment
Gurevitz, S. A., & Stone, M. J. (2012) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2012.11928822 · Cited by 73
Suhr, O. B., Lindqvist, P., Olofsson, B., Waldenström, A. P., & Backman, C. (2006) · Amyloid · doi:10.1080/13506120600876849 · Cited by 68
Self-citation
Cited by
Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
Maurer, M. S., Elliott, P., Comenzo, R., Semigran, M., & Rapezzi, C. (2017) · Circulation · doi:10.1161/circulationaha.116.024438 · Cited by 492
Self-citationDiagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis
Gertz, M. A., Benson, M. D., Dyck, P. J., Grogan, M., Coelho, T., Cruz, M., Berk, J. L., Plante-Bordeneuve, V., Schmidt, H. H. J., & Merlini, G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.075 · Cited by 475
Self-citationVutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Fontana, M., Berk, J. L., Gillmore, J. D., Witteles, R. M., Grogan, M., Drachman, B., Damy, T., Garcia-Pavia, P., Taubel, J., Solomon, S. D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409134 · Cited by 462
Self-citationPatisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
Maurer, M. S., Kale, P., Fontana, M., Berk, J. L., Grogan, M., Gustafsson, F., Hung, R. R., Gottlieb, R. L., Damy, T., González-Duarte, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300757 · Cited by 339
Self-citationSystemic amyloidosis from A (AA) to T (ATTR): a review
Muchtar, E., Dispenzieri, A., Magen, H., Grogan, M., Mauermann, M., McPhail, E. D., Kurtin, P. J., Leung, N., Buadi, F. K., Dingli, D., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13169 · Cited by 327
Metadata
- Authors
- Coelho, T., Maurer, M. S., & Suhr, O. B.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2012-12-13
- Volume
- 29
- Issue
- 1
- Pages
- 63-76
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2118369819
- Cited by
- 339
- References
- 24
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.